Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense) (Tables)

Other Income / (Expense) (Tables)

6 Months Ended

Dec. 31, 2023

Schedule of the components of other income (expense)

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):


	Quarter Ended					Six Months Ended
	December 31,					December 31,
	2023		2022		2023		2022
Interest expense	$	(4,329)	$	(2,356)	$	(9,222)	$	(6,146)
Interest income		816		968		1,706		1,401
Gain (loss) on investment⁽¹⁾		—		—		283		49,695
Gain (loss) on equity method investment		(1,914)		—		(4,204)		—
Other non-operating income (expense), net		810		(74)		516		988
Total other income (expense)	$	(4,617)	$	(1,462)	$	(10,921)	$	45,938

⁽¹⁾Primarily due to a $0.3 million gain on the sale of our exchange traded investment grade bond funds during the six months ended December 31, 2023 compared to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence in the six months ended December 31, 2022.